Abstract
Despite increasing therapeutic options and evolving treatment strategies, including targeting 3 therapeutic pathways, in the management of pulmonary arterial hypertension (PAH), morbidity and mortality have remained unacceptably high. Sotatercept is a first-in-class, novel activin signaling inhibitor approved for treating PAH based on evolving efficacy and safety evidence. This state-of-the-art review summarizes the current understanding of the mechanism of action, the impact on outcomes that improve how patients feel, function, and survive, and the safety and adverse event profile to inform readers of this breakthrough novel therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 1-10 |
Number of pages | 10 |
Journal | Journal of Heart and Lung Transplantation |
Volume | 44 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2025 |
Keywords
- outcomes
- pulmonary arterial hypertension
- sotatercept
- survival
- treatment
- Recombinant Fusion Proteins/therapeutic use
- Humans
- Pulmonary Arterial Hypertension/drug therapy
- Treatment Outcome
- Activin Receptors, Type II/therapeutic use
ASJC Scopus subject areas
- Surgery
- Pulmonary and Respiratory Medicine
- Cardiology and Cardiovascular Medicine
- Transplantation